[go: up one dir, main page]

FR20C1022I1 - - Google Patents

Info

Publication number
FR20C1022I1
FR20C1022I1 FR20C1022C FR20C1022I1 FR 20C1022 I1 FR20C1022 I1 FR 20C1022I1 FR 20C1022 C FR20C1022 C FR 20C1022C FR 20C1022 I1 FR20C1022 I1 FR 20C1022I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41435196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1022(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR20C1022I1 publication Critical patent/FR20C1022I1/fr
Application granted granted Critical
Publication of FR20C1022I2 publication Critical patent/FR20C1022I2/en
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
FR20C1022C 2008-12-22 2020-06-18 DOSAGE OF AN S1P RECEPTOR AGONIST Active FR20C1022I2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13967308P 2008-12-22 2008-12-22
EP09167209 2009-08-04
EP09793546.4A EP2379069B1 (en) 2008-12-22 2009-12-21 Dosage regimen of an s1p receptor agonist
PCT/EP2009/067618 WO2010072703A1 (en) 2008-12-22 2009-12-21 Dosage regimen of an s1p receptor agonist

Publications (2)

Publication Number Publication Date
FR20C1022I1 true FR20C1022I1 (en) 2020-07-31
FR20C1022I2 FR20C1022I2 (en) 2021-06-11

Family

ID=41435196

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1022C Active FR20C1022I2 (en) 2008-12-22 2020-06-18 DOSAGE OF AN S1P RECEPTOR AGONIST

Country Status (35)

Country Link
US (2) US8492441B2 (en)
EP (1) EP2379069B1 (en)
JP (2) JP5657565B2 (en)
KR (1) KR101660555B1 (en)
CN (2) CN105213372A (en)
AR (1) AR074825A1 (en)
AU (1) AU2009331582B2 (en)
BR (1) BRPI0923213A2 (en)
CA (3) CA2981830A1 (en)
CY (2) CY1116321T1 (en)
DK (1) DK2379069T3 (en)
ES (1) ES2538413T3 (en)
FR (1) FR20C1022I2 (en)
HK (1) HK1159524A1 (en)
HR (1) HRP20150567T1 (en)
HU (2) HUE026400T2 (en)
IL (2) IL294658A (en)
JO (1) JO3044B1 (en)
LT (1) LTC2379069I2 (en)
LU (1) LUC00160I2 (en)
MA (1) MA32907B1 (en)
MX (2) MX367667B (en)
NL (1) NL301046I2 (en)
NO (1) NO2020017I1 (en)
NZ (1) NZ593427A (en)
PL (1) PL2379069T3 (en)
PT (1) PT2379069E (en)
RU (1) RU2561681C2 (en)
SG (1) SG171888A1 (en)
SI (1) SI2379069T1 (en)
TN (1) TN2011000281A1 (en)
TW (1) TWI472327B (en)
UY (1) UY32350A (en)
WO (1) WO2010072703A1 (en)
ZA (1) ZA201104102B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009227629B2 (en) 2008-03-17 2014-09-04 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
EP2307007B1 (en) * 2008-07-23 2014-08-27 Novartis AG Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
US20100160259A1 (en) 2008-12-22 2010-06-24 Robert Schmouder Dosage regimen for a s1p receptor agonist
EP3378854B1 (en) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
AU2011249789B2 (en) * 2010-05-06 2015-03-19 Novartis Ag Dosage regimen of diaryl sulfide derivatives
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
JO3619B1 (en) 2011-01-07 2020-08-27 Novartis Ag Immunosuppressive formulations
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
WO2013057212A1 (en) * 2011-10-21 2013-04-25 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
CN104540800B (en) 2012-08-17 2017-05-10 埃科特莱茵药品有限公司 Process for the preparation of (2Z,5Z)-5-(3-chloro-4- ((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process
EP4191245A3 (en) 2013-04-04 2023-07-12 Novartis AG Identifying patient response to s1p receptor modulator administration
EP3129006B1 (en) * 2014-04-10 2021-01-27 Novartis AG Immunosuppressant formulation
WO2015155709A1 (en) * 2014-04-10 2015-10-15 Novartis Ag S1p modulator immediate release dosage regimen
EA036075B1 (en) 2014-12-11 2020-09-23 Актелион Фармасьютиклз Лтд Dosing regimen for a selective s1p1 receptor agonist
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
KR102603199B1 (en) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta for use in S1P1 receptor-related disorders [B]Indole-3-yl)crystalline L-arginine salt of acetic acid (Compound 1)
WO2018151834A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
KR20190116416A (en) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. Compounds and Methods for Treating Primary Bile Cholangitis
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Oxime ether compounds
AU2018341154A1 (en) * 2017-09-29 2020-03-12 Novartis Ag Dosing regimen of siponimod
CA3074416A1 (en) * 2017-09-29 2019-04-04 Novartis Ag Dosing regimen of siponimod
BR112020024762A2 (en) 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. methods of treating conditions related to the s1p1 receptor
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
WO2021158838A1 (en) 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
JP2024506041A (en) 2021-02-08 2024-02-08 ボシュ ヘルス アイルランド リミテッド Amicelimod to prevent, treat, or ameliorate ulcerative colitis
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1176819A (en) * 1997-09-03 1998-03-25 王树生 Sobering beverage and method for preparing same
DK1505959T3 (en) 2002-05-16 2009-02-23 Novartis Ag Use of EDG receptor binding agents in cancer
EP2644195A1 (en) 2003-05-19 2013-10-02 Irm Llc Immunosuppressant Compounds and Compositions
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
MXPA06004752A (en) * 2003-10-29 2006-07-05 Wyeth Corp Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof.
JPWO2005058316A1 (en) 2003-12-17 2007-07-12 大日本住友製薬株式会社 Combinations and combinations
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
SG187468A1 (en) * 2004-11-29 2013-02-28 Novartis Ag Dosage regimen of an s1p receptor agonist
BRPI0615860B8 (en) * 2005-09-09 2021-05-25 Labopharm Barbados Ltd solid monolithic extended release pharmaceutical composition
WO2008072056A1 (en) * 2006-12-14 2008-06-19 Pfizer Limited Use of mtp inhibitors for the treatment of obesity using low doses and dose-escalation
DE102007019417A1 (en) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol for the treatment of pain in osteoarthritis
HUE053835T2 (en) * 2007-10-12 2021-07-28 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators

Also Published As

Publication number Publication date
JP5657565B2 (en) 2015-01-21
TW201028147A (en) 2010-08-01
HK1159524A1 (en) 2012-08-03
JP2012513378A (en) 2012-06-14
HUE026400T2 (en) 2016-06-28
IL294658A (en) 2022-09-01
CN105213372A (en) 2016-01-06
KR101660555B1 (en) 2016-09-27
WO2010072703A1 (en) 2010-07-01
CN102264363A (en) 2011-11-30
DK2379069T3 (en) 2015-06-08
AR074825A1 (en) 2011-02-16
NO2020017I1 (en) 2020-06-17
US8492441B2 (en) 2013-07-23
TN2011000281A1 (en) 2012-12-17
IL213347B (en) 2019-11-28
RU2561681C2 (en) 2015-08-27
SG171888A1 (en) 2011-07-28
CA2747992C (en) 2017-11-07
NL301046I1 (en) 2020-06-17
ZA201104102B (en) 2012-02-29
CA3105857A1 (en) 2010-07-01
CA3105857C (en) 2023-08-01
TWI472327B (en) 2015-02-11
JP2015038097A (en) 2015-02-26
CY2020014I1 (en) 2020-11-25
CY2020014I2 (en) 2020-11-25
SI2379069T1 (en) 2015-07-31
BRPI0923213A2 (en) 2016-01-26
EP2379069B1 (en) 2015-03-04
KR20110106399A (en) 2011-09-28
HUS2000017I1 (en) 2020-07-28
MX2011006625A (en) 2011-09-28
NL301046I2 (en) 2020-07-29
LTC2379069I2 (en) 2022-05-25
PT2379069E (en) 2015-07-03
EP2379069A1 (en) 2011-10-26
CA2747992A1 (en) 2010-07-01
UY32350A (en) 2010-04-30
FR20C1022I2 (en) 2021-06-11
LUC00160I2 (en) 2021-07-06
ES2538413T3 (en) 2015-06-19
AU2009331582B2 (en) 2014-03-13
LUC00160I1 (en) 2020-06-19
IL213347A0 (en) 2011-07-31
PL2379069T3 (en) 2015-08-31
NZ593427A (en) 2013-11-29
AU2009331582A1 (en) 2011-06-30
MX367667B (en) 2019-08-30
US20130281712A1 (en) 2013-10-24
LTPA2020513I1 (en) 2020-07-27
HRP20150567T1 (en) 2015-08-14
US20110039818A1 (en) 2011-02-17
CA2981830A1 (en) 2010-07-01
CY1116321T1 (en) 2017-02-08
JO3044B1 (en) 2016-09-05
JP5941110B2 (en) 2016-06-29
MA32907B1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
LUC00160I2 (en)
BRPI0909040A2 (en)
BRPI0917573A2 (en)
BRPI0908549B8 (en)
BRPI0918697A2 (en)
BRPI0917525A2 (en)
BRPI0920750A2 (en)
BRPI0919470A2 (en)
BRPI0922455A2 (en)
BRPI0907698A2 (en)
BRPI0917618A8 (en)
BRPI0923734A2 (en)
BRPI0912727A2 (en)
BRPI0922669A2 (en)
BRPI0908285A2 (en)
BRPI0910485A2 (en)
BRPI0914750A2 (en)
BRPI0908120A2 (en)
BRPI0919811A2 (en)
BRPI0915616A2 (en)
BRPI0904541A8 (en)
BRPI0912462A2 (en)
BRPI0920914A2 (en)
BRPI0922550A2 (en)
BRPI0916284A2 (en)